|
TSPAN13 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
8.612300E-04 |
| Normal-vs-Stage3 |
1.77680004043168E-09 |
| Normal-vs-Stage4 |
4.556500E-04 |
| Stage1-vs-Stage2 |
6.190100E-02 |
| Stage1-vs-Stage3 |
2.003700E-02 |
| Stage1-vs-Stage4 |
1.306230E-02 |
| Stage2-vs-Stage3 |
8.438400E-01 |
| Stage2-vs-Stage4 |
7.049600E-01 |
| Stage3-vs-Stage4 |
4.600400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
5.63399999999881E-05 |
| Normal-vs-Asian |
9.41109967733667E-10 |
| Caucasian-vs-AfricanAmerican |
4.377400E-01 |
| Caucasian-vs-Asian |
3.333600E-01 |
| AfricanAmerican-vs-Asian |
9.519400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.36760003321967E-09 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
1.831630E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62470037423645E-12 |
| Normal-vs-Age(61-80Yrs) |
1.86723999999749E-05 |
| Normal-vs-Age(81-100Yrs) |
2.836200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.191400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.139700E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.133200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.348200E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.845400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.108400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.458180E-02 |
| Classical-VS-Follicular |
1.516110E-03 |
| Classical-VS-Other |
7.626600E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
9.246600E-01 |
| Tall-VS-Other |
3.347600E-01 |
| Tall-VS-Normal |
4.391900E-04 |
| Follicular-VS-Other |
1.915250E-01 |
| Follicular-VS-Normal |
1.84329999999289E-05 |
| Other-VS-Normal |
5.428400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.105427357601E-15 |
| Normal-vs-N1 |
3.42289999677448E-08 |
| N0-vs-N1 |
3.263400E-01 |
|
|
